Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect
of latanoprost and travoprost as primary therapy in patients with chronic angle-closure
glaucoma (CACG) after peripheral iridotomy.
Methods: Seventy-three (73) CACG patients with IOP > 19 mmHg after peripheral iridotomy
and without previous antiglaucoma medication were consecutively recruited. CACG
was defined as the presence of chronically elevated IOP, glaucomatous optic neuropathy, and
a corresponding visual field defect in eyes with occludable angle and peripheral anterior
synechiae on gonioscopy. Patients were randomly assigned to 2 groups, based on daily treatment
with either latanoprost 0.005% or travoprost 0.004% in the evening for 12 weeks. The
IOP was measured at 9 AM and 4 PM at baseline and at 4, 8, and 12 weeks. Between-group differences
in mean diurnal IOP and IOP reduction were analyzed.
Results: After 12 weeks of treatment, mean IOP for both the latanoprost and travoprost
groups was significantly reduced, when compared to the baseline IOP (from 21.3 ± 1.8 mmHg
to 16.0 ± 2.3 mmHg and 21.7 ± 1.7 to 16.7 ± 2.2 mmHg; P < 0.001 for both). There was no significant
difference in IOP reduction between the 2 treatment groups (P = 0.19). At 4 and 8
weeks, the IOP changes from the baseline were statistically significant at all time points for
both drugs (all P < 0.001).
Conclusions: Both latanoprost and travoprost significantly reduced IOP in our sample of
CACG patients after peripheral iridotomy.
